Baidu
map

Crit Care:危重病人血小板输注与医院获得性感染有关吗?

2017-07-16 MedSci MedSci原创

重症患者通常都有输注血小板的病史,目前已有报告显示输注血小板与感染之间有一定关系。然而,目前还没有大量的研究明确重症患者的血小板输注是否与医院获得性感染有关。

重症患者通常都有输注血小板的病史,目前已有报告显示输注血小板与感染之间有一定关系。然而,目前还没有大量的研究明确重症患者的血小板输注是否与医院获得性感染有关。

我们对澳大利亚的两所大型重症监护室(ICU)进行了一项多中心前瞻性研究。对2008年至2014年之间接受输注血小板的患者及无血小板输注病史的患者进行对比。采用多元Logistic回归和Cox的回归,利用血液成分随时间变化的协变量对血小板输注和感染(菌血症和/或尿路感染)的关系进行分析。以趋势协变量调整对结果进行验证。

共有18965例患者被纳入研究,其中2250(11.9%)在ICU住院过程中输注1个单位血小板(IQR 1-3)。与未输注血小板的患者相比,输注血小板的患者表现出病情更重(平均急性生理学与慢性健康状况评分分别为65(SD 29)和52(SD 25),P<0.01),同时并发症更多(31% vs 19%,P<0.01)。在输注血小板的患者中,进行有创机械通气(87% vs 57%,P<0.01)和肾脏替代治疗(20% vs 4%,P<0.01)的比率也较未输注血小板的患者更大。在单变量分析中,血小板输注与ICU院内感染密切相关(7.7% vs 1.4%,P<0.01)。调整混杂因素显示 ,其他血液成分、病情的严重程度、卫生机构、年龄和诊断范畴与血小板输注和院内感染的发生独立相关(OR 2.56 95% CI 1.98-3.31,P<0.001)。趋向性调节显示血小板输注与感染相关。

经调整混杂因素,患者病情严重程度、其他血液成分、血小板输注都与ICU获得性感染是独立相关的。进一步的研究旨在更清楚的解释此种联系从而必要的预防有关并发症的发生。

原始出处:

Cécile Aubron1,10 Andrew W. Flint,et al. Is platelet transfusion associated with hospital-acquired infections in critically ill patients? Crit Care. 2017; 21: 2.Published online 2017 Jan 6. doi:  10.1186/s13054-016-1593-x.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1690445, encodeId=6bdb16904459e, content=<a href='/topic/show?id=fdb336e49bb' target=_blank style='color:#2F92EE;'>#危重病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36749, encryptionId=fdb336e49bb, topicName=危重病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27f729051889, createdName=xinmeili, createdTime=Tue Oct 17 17:53:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042595, encodeId=6ddf204259584, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Wed Dec 27 06:53:00 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370275, encodeId=3fc713e027584, content=<a href='/topic/show?id=780c890604f' target=_blank style='color:#2F92EE;'>#血小板输注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89060, encryptionId=780c890604f, topicName=血小板输注)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Tue Jul 18 06:53:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533240, encodeId=d2001533240ca, content=<a href='/topic/show?id=c3c236e5229' target=_blank style='color:#2F92EE;'>#危重病人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36752, encryptionId=c3c236e5229, topicName=危重病人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53bc12401014, createdName=listen322, createdTime=Tue Jul 18 06:53:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222956, encodeId=c9f4222956eb, content=学习了许多先进的医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161027/IMG58114E1818EA51495.jpg, createdBy=4b2c1959822, createdName=雅文博武, createdTime=Sun Jul 16 16:14:13 CST 2017, time=2017-07-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1690445, encodeId=6bdb16904459e, content=<a href='/topic/show?id=fdb336e49bb' target=_blank style='color:#2F92EE;'>#危重病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36749, encryptionId=fdb336e49bb, topicName=危重病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27f729051889, createdName=xinmeili, createdTime=Tue Oct 17 17:53:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042595, encodeId=6ddf204259584, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Wed Dec 27 06:53:00 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370275, encodeId=3fc713e027584, content=<a href='/topic/show?id=780c890604f' target=_blank style='color:#2F92EE;'>#血小板输注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89060, encryptionId=780c890604f, topicName=血小板输注)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Tue Jul 18 06:53:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533240, encodeId=d2001533240ca, content=<a href='/topic/show?id=c3c236e5229' target=_blank style='color:#2F92EE;'>#危重病人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36752, encryptionId=c3c236e5229, topicName=危重病人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53bc12401014, createdName=listen322, createdTime=Tue Jul 18 06:53:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222956, encodeId=c9f4222956eb, content=学习了许多先进的医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161027/IMG58114E1818EA51495.jpg, createdBy=4b2c1959822, createdName=雅文博武, createdTime=Sun Jul 16 16:14:13 CST 2017, time=2017-07-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1690445, encodeId=6bdb16904459e, content=<a href='/topic/show?id=fdb336e49bb' target=_blank style='color:#2F92EE;'>#危重病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36749, encryptionId=fdb336e49bb, topicName=危重病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27f729051889, createdName=xinmeili, createdTime=Tue Oct 17 17:53:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042595, encodeId=6ddf204259584, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Wed Dec 27 06:53:00 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370275, encodeId=3fc713e027584, content=<a href='/topic/show?id=780c890604f' target=_blank style='color:#2F92EE;'>#血小板输注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89060, encryptionId=780c890604f, topicName=血小板输注)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Tue Jul 18 06:53:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533240, encodeId=d2001533240ca, content=<a href='/topic/show?id=c3c236e5229' target=_blank style='color:#2F92EE;'>#危重病人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36752, encryptionId=c3c236e5229, topicName=危重病人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53bc12401014, createdName=listen322, createdTime=Tue Jul 18 06:53:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222956, encodeId=c9f4222956eb, content=学习了许多先进的医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161027/IMG58114E1818EA51495.jpg, createdBy=4b2c1959822, createdName=雅文博武, createdTime=Sun Jul 16 16:14:13 CST 2017, time=2017-07-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1690445, encodeId=6bdb16904459e, content=<a href='/topic/show?id=fdb336e49bb' target=_blank style='color:#2F92EE;'>#危重病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36749, encryptionId=fdb336e49bb, topicName=危重病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27f729051889, createdName=xinmeili, createdTime=Tue Oct 17 17:53:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042595, encodeId=6ddf204259584, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Wed Dec 27 06:53:00 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370275, encodeId=3fc713e027584, content=<a href='/topic/show?id=780c890604f' target=_blank style='color:#2F92EE;'>#血小板输注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89060, encryptionId=780c890604f, topicName=血小板输注)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Tue Jul 18 06:53:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533240, encodeId=d2001533240ca, content=<a href='/topic/show?id=c3c236e5229' target=_blank style='color:#2F92EE;'>#危重病人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36752, encryptionId=c3c236e5229, topicName=危重病人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53bc12401014, createdName=listen322, createdTime=Tue Jul 18 06:53:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222956, encodeId=c9f4222956eb, content=学习了许多先进的医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161027/IMG58114E1818EA51495.jpg, createdBy=4b2c1959822, createdName=雅文博武, createdTime=Sun Jul 16 16:14:13 CST 2017, time=2017-07-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1690445, encodeId=6bdb16904459e, content=<a href='/topic/show?id=fdb336e49bb' target=_blank style='color:#2F92EE;'>#危重病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36749, encryptionId=fdb336e49bb, topicName=危重病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27f729051889, createdName=xinmeili, createdTime=Tue Oct 17 17:53:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042595, encodeId=6ddf204259584, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Wed Dec 27 06:53:00 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370275, encodeId=3fc713e027584, content=<a href='/topic/show?id=780c890604f' target=_blank style='color:#2F92EE;'>#血小板输注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89060, encryptionId=780c890604f, topicName=血小板输注)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Tue Jul 18 06:53:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533240, encodeId=d2001533240ca, content=<a href='/topic/show?id=c3c236e5229' target=_blank style='color:#2F92EE;'>#危重病人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36752, encryptionId=c3c236e5229, topicName=危重病人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53bc12401014, createdName=listen322, createdTime=Tue Jul 18 06:53:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222956, encodeId=c9f4222956eb, content=学习了许多先进的医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161027/IMG58114E1818EA51495.jpg, createdBy=4b2c1959822, createdName=雅文博武, createdTime=Sun Jul 16 16:14:13 CST 2017, time=2017-07-16, status=1, ipAttribution=)]
    2017-07-16 雅文博武

    学习了许多先进的医学知识

    0

相关资讯

Blood:血小板ADP受体在卵巢癌生长中的作用

血小板受体P2Y12在血小板和癌细胞间的相互作用中很重要。P2Y12抑制剂或P2Y12缺陷可减少卵巢癌的小鼠模型的肿瘤生长。

Clin Gastroenterol Hepatol:服用抗血小板药物合并胃肠道出血的病人输注血小板能否获益?

背景、目的:抗血小板药物能减少心血管不良事件,但会增加胃肠道出血风险。指南建议服用抗血小板药物合并严重胃肠道出血的病人输注血小板。我们拟探究上述病人输注血小板后,再出血风险是否降低及心血管事件是否增加。 方法:我们进行了一项回顾性队列研究,纳入2008年至2013年收治于耶鲁-纽黑文医院的胃肠道出血病人,病人均服用抗血小板药物、且血小板计数高于100*109/L。观察组(输注血小板,n=20

生物谷推荐:5月必看的重磅级研究Top10

转眼间5月份就快要过去了,这个月又有哪些研究论文值得我们深入学习一下呢?小编根据本月新闻的点击量、研究领域、热度筛选出了5月份的重磅级研究Top10,供大家学习交流。 【1】Mol Ther:重磅!科学家成功利用CRISPR/Cas9消除活体动物的HIV-1感染 doi:10.1016/j.ymthe.2017.03.012 由于病毒能够在潜在的病毒库中隐藏起来,因此彻底治愈HIV感染

Redox Biol:HPW-RX40具有作为新型抗血栓药物的潜力

PDI(蛋白二硫键异构酶)存在于血小板表面,因其在整合素糖蛋白IIb/IIIa(GPIIb/IIIa)的构象变化和活化中的重要作用而促进血小板聚集。许多研究表明,PDI可作为开发新一类抗血栓药物的潜在靶标。据此,研究人员调查了HPW-RX40对血小板活化和PDI活性的影响。

Blood:骨髓纤维化患者停用卢索替尼后的存活期情况

骨髓纤维化患者停用卢索替尼(ruxolitinib)后存活期很短,平均约14个月。在治疗初期或结束时出现低血小板或治疗中出现无性扩增都提示预后不良。尽管对于骨髓纤维化(MF)的标志和症状方面的认知都有明显提高,可以延长患者的存活期,但有些病人对卢索替尼不敏感,还有些人错失其反应时间。携带3个以上突变的患者基本都对卢索替尼不敏感。

Blood:输注红细胞或血小板对出血的影响以及出血的相关参数。

对多天出血的患者输注红细胞或血小板不会明显改变其随后的出血情况。因为在接受异体造血干细胞移植或化疗的患者人群,出血是在血小板计数的一个很宽的范围内发生,而输注血小板可能不能阻止出血,其中或许还涉及其他危险因子。可能包括低红细胞压积和凝血功能异常。

Baidu
map
Baidu
map
Baidu
map